Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino

Detalhes bibliográficos
Ano de defesa: 2008
Autor(a) principal: Lopes, Paulo Guilherme Markus
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
dARK ID: ark:/26339/0013000002w12
Idioma: por
Instituição de defesa: Universidade Federal de Santa Maria
Brasil
Farmácia
UFSM
Programa de Pós-Graduação em Ciências Farmacêuticas
Centro de Ciências da Saúde
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://repositorio.ufsm.br/handle/1/27362
Resumo: The approval of the protocol M-38A by Clinical and Laboratory Standards Institute (CLSI), which established standardized procedures for the evaluation of the in vitro susceptibility of moulds, has expanded the inherent knowledge about the fungi susceptibility against the most commonly used antifungal drugs. In this study, fortyone Sporothrix schenckii clinical isolates from both animals and humans have had their in vitro susceptibility against miconazole, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, caspofungin and amphotericin B tested, by the microdilution method, established by the protocol M-38A. The isolates have shown the highest in vitro susceptibility to terbinafine (MIC90= 0.25 μg/mL) and the lowest to fluconazole (MIC90= 128 μg/mL). Thirty-five isolates (85.37%) have shown MIC < 1.0 μg/mL against itraconazole while three isolates have shown MIC > 16 μg/mL. Regarding voriconazole (MIC90= 16 μg/mL) and caspofungin (MIC90= 32 μg/mL), the MIC values found demonstrate a profile of low susceptibility of the tested isolates. The MIC values found for amphotericin B (MIC90 = 1 μg/mL), have shown a profile of sensibility of the isolates evaluated in this study. In the evaluation of disseminated sporotrichosis in murine models, the treatment efficacy with itraconazole, voriconazole and amphotericin B were determined and compared. The antifungal therapy with amphotericin B have shown higher effectiveness compared to the control group (p<0.001) and to the other treatments (p<0.05). Through the subdivision of the mice’s groups by gender, could be observed a variation in the extension of Sporothrix schenckii disseminated infection, with males showing more damaged organs (p<0.05).
id UFSM_6cb58fd06b0ebc93d279f07a93879405
oai_identifier_str oai:repositorio.ufsm.br:1/27362
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murinoIn vitro susceptibility of Sporothrix schenckii and evaluation of antifungal therapy in a murine model of systemic sporotrichosisSporothrix schenckiiAntifúngicosSuscetibilidadeIn vitroIn vivoAntifungalSusceptibilityCNPQ::CIENCIAS DA SAUDE::FARMACIAThe approval of the protocol M-38A by Clinical and Laboratory Standards Institute (CLSI), which established standardized procedures for the evaluation of the in vitro susceptibility of moulds, has expanded the inherent knowledge about the fungi susceptibility against the most commonly used antifungal drugs. In this study, fortyone Sporothrix schenckii clinical isolates from both animals and humans have had their in vitro susceptibility against miconazole, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, caspofungin and amphotericin B tested, by the microdilution method, established by the protocol M-38A. The isolates have shown the highest in vitro susceptibility to terbinafine (MIC90= 0.25 μg/mL) and the lowest to fluconazole (MIC90= 128 μg/mL). Thirty-five isolates (85.37%) have shown MIC < 1.0 μg/mL against itraconazole while three isolates have shown MIC > 16 μg/mL. Regarding voriconazole (MIC90= 16 μg/mL) and caspofungin (MIC90= 32 μg/mL), the MIC values found demonstrate a profile of low susceptibility of the tested isolates. The MIC values found for amphotericin B (MIC90 = 1 μg/mL), have shown a profile of sensibility of the isolates evaluated in this study. In the evaluation of disseminated sporotrichosis in murine models, the treatment efficacy with itraconazole, voriconazole and amphotericin B were determined and compared. The antifungal therapy with amphotericin B have shown higher effectiveness compared to the control group (p<0.001) and to the other treatments (p<0.05). Through the subdivision of the mice’s groups by gender, could be observed a variation in the extension of Sporothrix schenckii disseminated infection, with males showing more damaged organs (p<0.05).A aprovação do protocolo M38-A pelo Clinical and Laboratory Standards Institute (CLSI), que estabelece normas padronizadas para avaliação de suscetibilidade in vitro de fungos filamentosos, tem expandido o conhecimento inerente aos aspectos de suscetibilidade destes fungos frente aos antifúngicos convencionalmente utilizados na prática clínica. Neste estudo, quarenta e um isolados clínicos de Sporothrix schenckii, oriundos de humanos e animais, foram avaliados quanto à suscetibilidade in vitro frente ao miconazol, cetoconazol, itraconazol, fluconazol, voriconazol, terbinafina, caspofungina e anfotericina B. Utilizou-se a metodologia de microdiluição em placa estabelecida pelo protocolo M38-A . Os isolados demonstraram maior suscetibilidade in vitro frente à terbinafina (CIM90= 0,25 μg/mL) e menor suscetibilidade ao fluconazol (CIM90= 128 μg/mL). Trinta e cinco isolados (85,37%) apresentaram CIM < 1,0 μg/mL frente ao itraconazol; em três isolados evidenciou-se CIM > 16 μg/mL. Quanto ao voriconazol (CIM90= 16 μg/mL) e a caspofungina (CIM90= 32 μg/mL), os valores de CIM encontrados demonstram um perfil de reduzida suscetibilidade dos isolados testados. As CIMs determinadas frente à anfotericina B (CIM90 = 1 μg/mL) puderam evidenciar um perfil de sensibilidade dos isolados avaliados neste estudo. Na avaliação da esporotricose disseminada em modelo murino, a eficácia de tratamento com itraconazol, voriconazol e anfotericina foram determinadas e comparadas. A antifungicoterapia com anfotericina B evidenciou maior efetividade em relação ao grupo controle (p<0,001) e aos demais tratamentos (p<0,05). Através da subdivisão dos grupos de camundongos por sexo, pôde ser observada uma variação na extensão da infecção disseminada por Sporothrix schenckii com maior comprometimento das vísceras dos machos (p<0,05).Universidade Federal de Santa MariaBrasilFarmáciaUFSMPrograma de Pós-Graduação em Ciências FarmacêuticasCentro de Ciências da SaúdeAlves, Sydney Hartzhttp://lattes.cnpq.br/0330782478769631Santurio, Jânio MoraisAthayde, Margareth LindeLopes, Paulo Guilherme Markus2022-12-15T16:53:46Z2022-12-15T16:53:46Z2008-03-19info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/27362ark:/26339/0013000002w12porAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2022-12-15T16:53:46Zoai:repositorio.ufsm.br:1/27362Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/PUBhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.bropendoar:2022-12-15T16:53:46Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
In vitro susceptibility of Sporothrix schenckii and evaluation of antifungal therapy in a murine model of systemic sporotrichosis
title Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
spellingShingle Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
Lopes, Paulo Guilherme Markus
Sporothrix schenckii
Antifúngicos
Suscetibilidade
In vitro
In vivo
Antifungal
Susceptibility
CNPQ::CIENCIAS DA SAUDE::FARMACIA
title_short Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
title_full Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
title_fullStr Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
title_full_unstemmed Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
title_sort Suscetibilidade in vitro de Sporothrix schenckii e avaliação da antifungicoterapia na esporotricose experimental em modelo murino
author Lopes, Paulo Guilherme Markus
author_facet Lopes, Paulo Guilherme Markus
author_role author
dc.contributor.none.fl_str_mv Alves, Sydney Hartz
http://lattes.cnpq.br/0330782478769631
Santurio, Jânio Morais
Athayde, Margareth Linde
dc.contributor.author.fl_str_mv Lopes, Paulo Guilherme Markus
dc.subject.por.fl_str_mv Sporothrix schenckii
Antifúngicos
Suscetibilidade
In vitro
In vivo
Antifungal
Susceptibility
CNPQ::CIENCIAS DA SAUDE::FARMACIA
topic Sporothrix schenckii
Antifúngicos
Suscetibilidade
In vitro
In vivo
Antifungal
Susceptibility
CNPQ::CIENCIAS DA SAUDE::FARMACIA
description The approval of the protocol M-38A by Clinical and Laboratory Standards Institute (CLSI), which established standardized procedures for the evaluation of the in vitro susceptibility of moulds, has expanded the inherent knowledge about the fungi susceptibility against the most commonly used antifungal drugs. In this study, fortyone Sporothrix schenckii clinical isolates from both animals and humans have had their in vitro susceptibility against miconazole, ketoconazole, itraconazole, fluconazole, voriconazole, terbinafine, caspofungin and amphotericin B tested, by the microdilution method, established by the protocol M-38A. The isolates have shown the highest in vitro susceptibility to terbinafine (MIC90= 0.25 μg/mL) and the lowest to fluconazole (MIC90= 128 μg/mL). Thirty-five isolates (85.37%) have shown MIC < 1.0 μg/mL against itraconazole while three isolates have shown MIC > 16 μg/mL. Regarding voriconazole (MIC90= 16 μg/mL) and caspofungin (MIC90= 32 μg/mL), the MIC values found demonstrate a profile of low susceptibility of the tested isolates. The MIC values found for amphotericin B (MIC90 = 1 μg/mL), have shown a profile of sensibility of the isolates evaluated in this study. In the evaluation of disseminated sporotrichosis in murine models, the treatment efficacy with itraconazole, voriconazole and amphotericin B were determined and compared. The antifungal therapy with amphotericin B have shown higher effectiveness compared to the control group (p<0.001) and to the other treatments (p<0.05). Through the subdivision of the mice’s groups by gender, could be observed a variation in the extension of Sporothrix schenckii disseminated infection, with males showing more damaged organs (p<0.05).
publishDate 2008
dc.date.none.fl_str_mv 2008-03-19
2022-12-15T16:53:46Z
2022-12-15T16:53:46Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/27362
dc.identifier.dark.fl_str_mv ark:/26339/0013000002w12
url http://repositorio.ufsm.br/handle/1/27362
identifier_str_mv ark:/26339/0013000002w12
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmácia
UFSM
Programa de Pós-Graduação em Ciências Farmacêuticas
Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmácia
UFSM
Programa de Pós-Graduação em Ciências Farmacêuticas
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.br
_version_ 1847153337569378304